California Code of Regulations › Title 17 - Public Health › Division 1 - State Department of Health Services › Chapter 5 - Sanitation (Environmental) › Subchapter 2 - Foods and Drugs › Group 1 - RULES AND REGULATIONS › Article 2 - DRUGS AND DEVICES REGULATIONS › Drugs and Devices › Section 10400.1 - Beta-Cyanogenetic Glucosides ( "Laetriles") Agent for Treatment of Cancer

Current through Register 2024 Notice Reg. No. 28, July 12, 2024
(a) The Department of
						  Public Health has carefully considered a document entitled "A Report on the
						  Treatment of Cancer with Beta-Cyanogenetic Glucosides ('Laetriles')" dated May 20,
						  1963, and is satisfied beyond a reasonable doubt that the findings therein are true.
						  The Department hereby ratifies and adopts said report as its own and a copy of same
						  is on file with the California State Department of Public Health and is available
						  for public inspection at its office located at 2151 Berkeley Way, Berkeley,
						  California.
(b) The Department of Public
						  Health hereby finds that beta-cyanogenetic glucosides including amygdalin (with or
						  without the addition of diisopropyl ammonium iodide), and prunasin, commonly known
						  as "Laetriles," are of no value in the diagnosis, treatment, alleviation or cure of
						  cancer and that the use of one or more of these agents in early cancer to the
						  exclusion of conventional treatment might well be dangerous since treatment with
						  acceptable, modern, curative methods (surgery or radiation) would thereby be delayed
						  potentially until such time as metastases had occurred and the cancer therefore
						  might no longer be curable. In late disease palliative effect is lacking. The
						  Department recommends that the public refrain from using any of the said agents or
						  any agent, drug, medicine, compound or device substantially similar thereto in the
						  diagnosis, alleviation, treatment or cure of cancer.
(c) Except as otherwise provided in Section
						  1708 of
						  the California Health and Safety Code the prescription, administration, sale or
						  other distribution of beta-cyanogenetic glucosides including amygdalin (with or
						  without the addition of diisopropyl ammonium iodide) and prunasin, commonly known as
						  "Laetriles" or, any substantially similar agent, drug, medicine, compound or device
						  to any patient who has or who believes that he has or may have cancer is prohibited;
						  and the Department shall upon learning of such prescription, administration, sale or
						  other distribution take appropriate steps to cause such persons so doing to cease
						  and desist therefrom.
(d) No person
						  shall for the purpose of prescribing, administering, selling or otherwise
						  distributing beta-cyanogenetic glucosides including amygdalin (with or without the
						  addition of diisopropyl ammonium iodide) or prunasin, commonly known as "Laetriles,"
						  make any representation that said agents have any value in arresting, alleviating or
						  curing cancer; and the Department shall upon learning of such representation take
						  appropriate steps to cause such person to cease and desist from such representation
						  and shall take such other and further steps as may be appropriate to cause such
						  representation to be discontinued.
1. New
							 section filed 10-3-63; effective thirtieth day thereafter (Register 63, No.
							 17).
Note: Authority cited: Sections
								102 and
								208,
								Health and Safety Code. Reference: Section
								1704,
								Health and Safety Code.